High-dose ifosfamide in the treatment of sarcomas of soft tissues and bone.
Ifosfamide is an alkylating agent with clinical activity in the treatment of sarcomas, and data support a dose-response relationship in this disease. Attaining a clinical response can be a significant end point in sarcomas because such a response may allow function-sparing surgery or improved surgical resection of bulky primary tumors. Studies have shown that higher response rates can be obtained in sarcomas using dose-intensified chemotherapy than with conventional-dose chemotherapy. Although the early data using high-dose ifosfamide in the treatment of sarcomas are promising, the median durations of response have been less than 1 year. The continuing advances in supportive care technology will facilitate the ability to conduct large-scale trials in sarcomas using dose-intensified chemotherapy. The aim of these trials should be to optimize the dosing and antineoplastic efficacy of ifosfamide as a single agent and in combination regimens.
Demetri
G D
GD
Sarcoma Program, Division of Cancer Pharmacology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.
D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage / Q000627:therapeutic use*; D012074:Remission Induction; D012509:Sarcoma / Q000188:drug therapy*; D012983:Soft Tissue Neoplasms / Q000188:drug therapy*
D018906:Antineoplastic Agents, Alkylating; D007069:Ifosfamide